Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : eNOfit is a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
Product Name : eNOfit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing
Details : Third Pole's technology generates pure inhaled nitric oxide (iNO) for therapeutic use and delivers it to the patient on demand, providing clinicians with greater flexibility than with iNO therapeutics stored in compressed gas cylinders.
Product Name : eNOfit
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing